Geniposide inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma

详细信息    查看全文

• 作者：Yanhong Deng ; Mingfeng Guan ; Xingxing Xie ; Xiaofeng Yang ; Hua Xiang ; Hongyu Li ; Lianchun Zou ; Jingyuan Wei ; Dacheng Wang ; Xuming Deng
• 关键词：Geniposide (Gen) ; Ovalbumin (Ova) ; Asthma ; Hyperresponsiveness ; Allergic airway inflammation ; Nuclear factor-kappaB (NF-魏B)
• 刊名：International Immunopharmacology
• 出版年：November, 2013
• 年：2013
• 卷：17
• 期：3
• 页码：561-567
• 全文大小：748 K

文摘

Our group recently reported the strong anti-inflammatory effects of geniposide (Gen), a bioactive iridoid glucoside derived from gardenia jasminoides, in a mouse acute lung injury model. Herein, we hypothesized that Gen might also have potential therapeutic benefits in treatment of asthma, which was tested in a mouse model of ovalbumin (Ova)-induced allergic airway inflammation. Ova-sensitized and -challenged BALB/c mice, as compared with control animals, displayed airway hyperresponsiveness (AHR), bronchoalveolar lavage eosinophilia, mucus hypersecretion, and increased T help 2 (Th2)-associated cytokine and chemokine amounts, as well as serum Ova-specific immunoglobulin E (IgE) level. Being compared with the Ova-induced hallmarks of asthma, intraperitoneal Gen treatment prevented eosinophilic pulmonary infiltration, attenuated the increases in interleukin (IL)-4, IL-5, and IL-13, and reduced eotaxin and vascular cell adhesion molecule 1 (VCAM-1) expression. Also, Gen significantly ameliorated the Ova-driven airway hyperresponsiveness, mucus hypersecretion, and allergen-specific IgE level, which are the cardinal pathophysiological symptoms in allergic airway diseases. In addition, the efficacy of Gen was comparable to that of dexamethasone (Dex), a currently available anti-asthmatic drug. Collectively, our findings reveal that the development of immunoregulatory strategies based on Gen may be considered as an effective adjuvant therapy for allergic asthma.